Effects of Huachansu capsules combined with raltitrexed and olisaplatin on advanced colorectal cancer immunity, tumor markers, matrix metalloproteinases and angiogenesis

Objective:To investigate the effects of Huachansu capsules combined with raltitrexed and olisaplatin on advanced colorectal cancer immunity, tumor markers, matrix metalloproteinases and angiogenesis.Methods: Eighty-two patients with advanced colorectal cancer who were treated in our hospital from August 2015 to September 2017 were randomly divided into the control group (41 cases) and the observation group (41 cases), the control group was treated with raltitrex plus oxaliplatin, on the basis of the control group, the observation group was treated with Huachansu Capsule. The levels of immune function, tumor markers, matrix metalloproteinases and angiogenic factors were compared before and after treatment in two groups of patients with advanced colorectal cancer.Results: After treatment, the levels of CD4+ and CD4+/CD8+ in the two groups were significantly higher than those before treatment (P<0.05), and the levels of CD4+ and CD4+/CD8+ in the observation group were significantly higher than those in the control group (P<0.05). the levels of CA125, CA19-9 and CEA in the two groups were significantly lower than those before treatment (P<0.05), and the levels of CA125, CA19-9 and CEA in the observation group were significantly lower than those in the control group (P<0.05);the levels of MMP-2 and MMP-9 in the two groups were significantly lower than those before treatment (P<0.05), and the levels of MMP-2 and MMP-9 in the observation group were significantly lower than those in the control group (P<0.05);the levels of VEGF, HIF-1α and TGF-β1 in the two groups were significantly lower than those before treatment (P<0.05), and the levels of VEGF, HIF-1α and TGF-β1 in the observation group were significantly lower than those in the control group (P<0.05).Conclusions: Huachansu Capsule combined with retidoxed and olixaplatin chemotherapy regimen can enhance the immune function of patients with advanced colorectal cancer, reduce the level of tumor markers in serum, inhibit the growth and metastasis of tumor cells and angiogenesis, which has clinical significance.

华蟾素胶囊联合雷替曲塞与奥利沙铂对晚期结直肠癌免疫、肿瘤标记物、基质金属蛋白酶及血管新生的影响

目的:探究华蟾素胶囊联合雷替曲塞与奥利沙铂对晚期结直肠癌免疫、肿瘤标记物、基质金属蛋白酶及血管新生的影响。方法:选择2015年8月～2017年9月我院接受治疗的晚期结直肠癌患者82例,随机分为对照组(41例)和观察组(41例),对照组予以雷替曲塞联用奥沙利铂治疗方案,观察组在对照组基础上,予以华蟾素胶囊治疗。比较2组晚期结直肠癌患者治疗前后免疫功能、肿瘤标记物、基质金属蛋白酶及血管新生因子的水平变化。结果:治疗后,两组CD4+及CD4+/CD8+水平较治疗前显著上升(P<0.05),且观察组CD4+及CD4+/CD8+水平显著高于对照组(P<0.05);两组糖类抗原125(CA125)、糖类抗原19-9(CA19-9)、癌胚抗原(CEA)水平较治疗前显著下降(P<0.05),且观察组CA125、CA19-9及CEA水平显著低于对照组(P<0.05);两组基质金属蛋白酶-2(MMP-2)、基质金属蛋白酶-9(MMP-9)水平较治疗前显著下降(P<0.05),且观察组MMP-2及MMP-9水平显著低于对照组(P<0.05);两组血管内皮生长因子(VEGF)、低氧诱导因子-1α(HIF-1α)、转化生长因子-β1(TGF-β1)水平较治疗前显著下降(P<0.05),且观察组VEGF、HIF-1α及TGF-β1水平显著低于对照组(P<0.05)。结论:华蟾素胶囊联合雷替曲塞与奥利沙铂化疗方案,可增强晚期结直肠癌患者免疫功能,降低血清中肿瘤标记物水平,抑制肿瘤细胞的生长转移及其血管新生,具有临床推广意义。